ABSI
Absci Corporation [ABSI] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ABSI Stock Summary
Top 10 Correlated ETFs
ABSI
Top 10 Correlated Stocks
ABSI
In the News
ABSI Financial details
Company Rating
-
Market Cap
657.54M
Income
-110.57M
Revenue
5.72M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
155
Optionable
No
Shortable
Yes
Earnings
13 May 2024
P/E
-3.56
Forward P/E
-
PEG
-8.19
P/S
55.06
P/B
1.93
P/C
-
P/FCF
-6.88
Quick Ratio
4.09
Current Ratio
4.82
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.2
EPS next Y
-
EPS next Q
-
EPS this Y
4.35%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
74.72%
Revenue last 5Y
22.65%
Revenue Q/Q
-54.57%
EPS Q/Q
4.17%
-
-
-
-
SMA20
-10%
SMA50
-
SMA100
50%
Inst Own
-
Inst Trans
-
ROA
-45%
ROE
-45%
ROC
-0.54%
Gross Margin
100%
Oper. Margin
-1613%
Profit Margin
-1535%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.111-6.72
52W High
+77.08%
52W Low
+962.5%
RSI
52
Rel Volume
3.1
Avg Volume
1.57M
Volume
4.85M
Perf Week
28.79%
Perf Month
33.82%
Perf Quarter
78.57%
Perf Half Y
198.46%
-
-
-
-
Beta
2.367
-
-
Volatility
0.63%, 0.83%
Prev Close
12.43%
Price
10.625
Change
15.61%
Company Profile
- Volume Average 1.57M
- Market Capitalization 657.54M
- Employee 155
- CEO Mr. Sean McClain
- Headquarters Vancouver,WA,US
- IPO Date 2021-07-22
-
Website
https://www.absci.com 
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.
